• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Thimble Point Acquisition Corp.

    12/8/21 5:15:56 PM ET
    $THMA
    Finance
    Get the next $THMA alert in real time by email
    SC 13G 1 d264931dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Amendment No.     )*

    Under the Securities Exchange Act of 1934

     

     

    Pear Therapeutics, Inc.

    (Name of Issuer)

    Class A Common Stock, par value $0.0001 per share

    (Titles of Class of Securities)

    704723105

    (CUSIP Number)

    December 3, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out of a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 704723105    SCHEDULE 13G    Page 2 of 8

     

      1    

      NAME OF REPORTING PERSON OR

      I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

      LJ10 LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      11,553,333 (1)(2)

       6   

      SHARED VOTING POWER

     

      0 (1)(2)

       7   

      SOLE DISPOSITIVE POWER

     

      11,553,333 (1)(2)

       8   

      SHARED DISPOSITIVE POWER

     

      0 (1)(2)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      11,553,333 (1)(2)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      8.09% (3)

    12  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    In connection with the closing of the business combination of Thimble Point Acquisition Corp. (the “Issuer”) with Pear Therapeutics, Inc. on December 3, 2021 (the “Business Combination”), the shares of Class B common stock, par value $0.0001 per share, of the Issuer were automatically converted into shares of Class A common stock, par value $0.0001 per share, of the Issuer (the “Common Stock”) on a one-for-one basis. In connection with the closing of the Business Combination, the Issuer changed its name from Thimble Point Acquisition Corp. to Pear Therapeutics, Inc.

    (2)

    Represents 6,540,000 shares of Common Stock held by LJ10 LLC (the “Sponsor”) and 5,013,333 shares of Common Stock issuable upon the exercise of 5,013,333 private placement warrants of the Issuer. Each private placement warrant is exercisable to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment, beginning on February 4, 2022 (the date that is within 60 days of December 6, 2021), and expires on December 3, 2026 or earlier upon redemption or liquidation. Elon S. Boms and two other managers are the three managers of the Sponsor’s board of managers. Any action by the Sponsor with respect to the Issuer or the Common Stock, including voting and dispositive decisions, requires at least a majority vote of the managers of the board of managers. Under the so-called “rule of three”, because voting and dispositive decisions are made by a majority of the managers, none of the named managers is deemed to be a beneficial owner of securities held by the Sponsor, even those in which such manager may hold a pecuniary interest. Accordingly, none of the managers on the Sponsor’s board of managers is deemed to have or share beneficial ownership of the shares of Common Stock held by the Sponsor.

    (3)

    Percentage based on 142,812,551 shares of Common Stock outstanding as of December 3, 2021 (representing 137,799,218 shares of Common Stock outstanding as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 8, 2021, as adjusted for the 5,013,333 shares of Common Stock underlying the private placement warrants).


    CUSIP No. 704723105    SCHEDULE 13G    Page 3 of 8

     

     

      1    

      NAME OF REPORTING PERSON OR

      I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

      KLP SPAC 1 LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      6,387,026 (1)

       6   

      SHARED VOTING POWER

     

      0 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      6,387,026 (1)

       8   

      SHARED DISPOSITIVE POWER

     

      0 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,387,026 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      4.64% (2)

    12  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    Represents 6,387,026 shares of Common Stock held by KLP SPAC 1 LLC (the “Anchor Investor”). The Anchor Investor purchased these shares in a private placement on December 3, 2021. Elon S. Boms and two other managers are the three managers of the Anchor Investor’s board of managers. Any action by the Anchor Investor with respect to the Issuer or the Common Stock, including voting and dispositive decisions, requires at least a majority vote of the managers of the board of managers. Under the so-called “rule of three”, because voting and dispositive decisions are made by a majority of the managers, none of the named managers is deemed to be a beneficial owner of securities held by the Anchor Investor, even those in which such manager may hold a pecuniary interest. Accordingly, none of the managers on the Anchor Investor’s board of managers is deemed to have or share beneficial ownership of the shares of Common Stock held by the Anchor Investor.

    (2)

    Percentage based on 137,799,218 shares of Common Stock outstanding as of December 3, 2021, as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 8, 2021.


    CUSIP No. 704723105    SCHEDULE 13G    Page 4 of 8

     

     

    Item 1(a).

    Name of Issuer:

    Pear Therapeutics, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    200 State Street, Boston, Massachusetts 02109

     

    Item 2(a).

    Name of Person Filing:

    This statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

    1. LJ10 LLC

    2. KLP SPAC 1 LLC

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

    The principal business address of each of the Reporting Persons is as follows:

    195 Church Street, 15th Floor

    New Haven, Connecticut 06510

     

    Item 2(c).

    Citizenship:

    See responses to Item 4 on each cover page.

     

    Item 2(d).

    Titles of Classes of Securities:

    Class A Common Stock, par value $0.0001 per share.

     

    Item 2(e).

    CUSIP Number:

    704723105


    CUSIP No. 704723105    SCHEDULE 13G    Page 5 of 8

     

    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n):

     

    (a)

       ☐    Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).

    (b)

       ☐    Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

    (c)

       ☐    Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

    (d)

       ☐    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

    (e)

       ☐    Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    (f)

       ☐    Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

    (g)

       ☐    Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

    (h)

       ☐    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

    (i)

       ☐    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

    (j)

       ☐    Non-U.S. institution, in accordance with § 240.13d-1(b)(1)(ii)(J).

    (k)

       ☐    Group in accordance with §240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership

     

      (a)

    Amount beneficially owned:

    See responses to Item 9 on each cover page.

     

      (b)

    Percent of class:

    See responses to Item 11 on each cover page.

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote:

    See responses to Item 5 on each cover page.

     

      (ii)

    Shared power to vote or to direct the vote:

    See responses to Item 6 on each cover page.


    CUSIP No. 704723105    SCHEDULE 13G    Page 6 of 8

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    See responses to Item 7 on each cover page.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    See responses to Item 8 on each cover page.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    The Reporting Persons may be deemed to be members of a “group,” within the meaning of Section 13(d)(3) of the Act, comprised of the Reporting Persons. See responses to Item 2.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    CUSIP No. 704723105    SCHEDULE 13G    Page 7 of 8

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: December 8, 2021

     

    LJ10 LLC
    By:  

    /s/ Elon S. Boms

    Name:   Elon S. Boms
    Title:   Manager
    KLP SPAC 1 LLC
    By:  

    /s/ Elon S. Boms

    Name:   Elon S. Boms
    Title:   Manager


    CUSIP No. 704723105    SCHEDULE 13G    Page 8 of 8

     

    Exhibit Index

     

    Exhibit No.   

    Description

    Exhibit 99.1    Joint Filing Agreement, dated as of December 8, 2021, by and among LJ10 LLC and KLP SPAC 1 LLC.
    Get the next $THMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THMA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $THMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics Company

    Publicly traded company called Pear Therapeutics, Inc. to begin trading on Nasdaq under ticker symbol "PEAR" starting December 6, 2021 Total expected gross proceeds from transaction totaling approximately $175 million Pear Therapeutics, Inc. ("Pear Therapeutics"), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), announced today the completion of its business combination with Thimble Point Acquisition Corp. ("Thimble Point") (NASDAQ:THMA), a special purpose acquisition company ("SPAC"). The publicly traded company will be known as Pear Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol "

    12/3/21 4:12:00 PM ET
    $THMA
    Finance

    Pear Therapeutics to Participate in Evercore ISI Fourth Annual HealthCONx Conference

    Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management will participate in the Evercore ISI Fourth Annual HealthCONx Conference on Wednesday, December 1, 2021. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 8:50 a.m. ET. A live audio webcast can be accessed by clicking here and will be made available on Pear's website at www.peartherapeutics.com. A replay will be available for approximately 30 days following the live presentation. About Pear Therapeutics Pear Therapeutics is the leader in prescription digital therapeutics, or PD

    11/23/21 8:00:00 AM ET
    $THMA
    Finance

    Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder

    Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its reSET-A™ PDT product candidate designed for the treatment of alcohol use disorder (AUD). reSET-A potentially expands Pear's addiction franchise, which includes FDA-authorized products to treat substance use disorder (SUD) and opioid use disorder (OUD). This is the second such Breakthrough Device Designation received by Pear, following the designation awarded for reSET-O®, the first ever for a PDT, which was for the treatment

    11/22/21 8:00:00 AM ET
    $THMA
    Finance

    $THMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider 5am Partners Iv, Llc claimed ownership of 18,631,771 shares

    3 - Pear Therapeutics, Inc. (0001835567) (Issuer)

    12/13/21 4:26:37 PM ET
    $THMA
    Finance

    SEC Form 4 filed by Bauerlein Alison

    4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

    12/10/21 4:47:18 PM ET
    $THMA
    Finance

    SEC Form 4 filed by Reddy Kirthiga

    4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

    12/10/21 4:46:17 PM ET
    $THMA
    Finance

    $THMA
    SEC Filings

    View All

    SEC Form 25-NSE filed by Thimble Point Acquisition Corp.

    25-NSE - Thimble Point Acquisition Corp. (0001835567) (Subject)

    12/3/21 4:02:15 PM ET
    $THMA
    Finance

    SEC Form 425 filed by Thimble Point Acquisition Corp.

    425 - Thimble Point Acquisition Corp. (0001835567) (Subject)

    11/30/21 4:42:53 PM ET
    $THMA
    Finance

    Thimble Point Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Thimble Point Acquisition Corp. (0001835567) (Filer)

    11/30/21 4:38:59 PM ET
    $THMA
    Finance

    $THMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Thimble Point Acquisition Corp.

    SC 13G - Pear Therapeutics, Inc. (0001835567) (Subject)

    12/13/21 4:30:52 PM ET
    $THMA
    Finance

    SEC Form SC 13D filed by Thimble Point Acquisition Corp.

    SC 13D - Pear Therapeutics, Inc. (0001835567) (Subject)

    12/13/21 4:16:57 PM ET
    $THMA
    Finance

    SEC Form SC 13D filed by Thimble Point Acquisition Corp.

    SC 13D - Pear Therapeutics, Inc. (0001835567) (Subject)

    12/13/21 4:16:15 PM ET
    $THMA
    Finance